JG
DNTH icon

Jain Global’s Dianthus Therapeutics DNTH Stock Holding History

Jain Global’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-23,694
Closed -$976K – 1310
2025
Q4 		$976K Buy
23,694
+12,570
+113% +$487K ﹤0.01% 711
2025
Q3 		$438K Buy
+11,124
New +$284K ﹤0.01% 755

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jain Global's DNTH Position: Q1 2026 in Review

Jain Global sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 23,694 shares — an estimated $976K sold.

Jain Global first reported a position in DNTH in Q3 2025 and held it in 2 quarters. The position peaked at $976K in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Jain Global reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jain Global sold 23,694 Dianthus Therapeutics shares in Q1 2026, an estimated $976K.
  • Jain Global first reported a position in Dianthus Therapeutics in Q3 2025 and held it in 2 quarters.
  • Jain Global's Dianthus Therapeutics position peaked at $976K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.